Q&A

Reducing CMC Risk From IND To Commerical Manufacturing Of Cell And Gene Therapies

Source: Cytiva

By J. Kelly Ganjei, CEO of Cognate BioServices, David Pryce, CEO of Devacel, Shailesh Maingi, Founder and Chairman of Kineticos Life Sciences, Beth Webb, Global GM for Commercial for Cell and Gene Therapy at Cytiva

iStock-1159995989-cell-gene-map

For those developing potentially curative therapies, it is a critical and exhilarating time. The industry now has some cell and gene therapy approvals, so the question has become: How can we quickly yet safely move new candidates through the clinic?

Experts from the cell and gene therapy field share experiences and discuss growing trends to accelerate treatments. Topics include transitioning from development, what to look for in a CDMO, moving from the bench to the clinic, timeline bottlenecks, approaching manufacturing with new models, how to fill the talent gap, how to advance clinical trials, when to start thinking about a technology transfer, and when in-house manufacturing makes sense.

Industry experts:
J. Kelly Ganjei, CEO of Cognate BioServices
David Pryce, CEO of Devacel
Shailesh Maingi, Founder and Chairman of Kineticos Life Sciences
Beth Webb, Global GM for Commercial for Cell and Gene Therapy at Cytiva

VIEW THE Q&A!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: